63285-60-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-METHYLPIPERAZINE-2-CARBOXYLATE is used as an intermediate in organic synthesis for the development of various pharmaceuticals and therapeutic drugs. Its unique structure and properties make it a key component in the creation of biologically active molecules, contributing to the advancement of new medications and treatments.
Used in Pharmaceutical Research:
As a derivative of piperazine, ETHYL 4-METHYLPIPERAZINE-2-CARBOXYLATE is utilized in pharmaceutical research to explore its potential applications and interactions with other compounds. This research helps in understanding the compound's role in drug development and its possible therapeutic effects, paving the way for innovative pharmaceutical solutions.

InChI:InChI=1/C8H16N2O2/c1-3-12-8(11)7-6-10(2)5-4-9-7/h7,9H,3-6H2,1-2H3

Upstream product

• 63285-59-6 ethyl 1-benzyl-4-methylpiperazine-2-carboxylate 
• 3674-13-3 2,3-dibromopropionic acid ethyl ester 

Downstream Products

• 85147-16-6 1-(2-Cyano-4-nitrophenyl)-4-methyl-2-piperazincarbonsaeure-aethylester 
• 688020-37-3 1-(1-benzyl-piperidin-4-yl)-4-methyl-piperazine-2-carboxylic acid ethyl ester 
• 64172-94-7 4-methyl-1-(2-nitro-phenyl)-piperazine-2-carboxylic acid 
• 85147-17-7 1-(4-Amino-2-cyanophenyl)-4-methyl-2-piperazincarbonsaeure-aethylester 
• 85147-19-9 1-(2-Cyanophenyl)-4-methyl-2-piperazincarbonsaeure-aethylester 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical　applications, especially for use in treating and preventing HBV diseases. Specifically,provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT

The invention relates to CGRP antagonists of general formula (I), in which A, U, V, W, X and R1 to R 3 are as defined in claim 1, the tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, hydrates of the salts, in particular the physiologically-acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds and the use and methods for production thereof.

Hybridized and isosteric analogues of N1-acetyl-N4-dimethyl-piperazinium iodide (ADMP) and N1-phenyl-N4-dimethyl-piperazinium iodide (DMPP) with central nicotinic action

A series of piperazine derivatives, obtained by hybridization of N1-acetyl-N4-dimethyl-piperazinium iodide (1, ADMP) and N1-phenyl-N4-dimethyl-piperazinium iodide (3, DMPP) or of the corresponding tertiary bases (2, 4) with arecoline (5) and arecolone (6) or by isosteric substitution of the phenyl ring of DMPP, has been synthesized. Hybridization afforded compounds that, both as tertiary bases and as iodomethylates, have no affinity for the nicotinic receptor. On the contrary, isosteric substitution gave compounds that maintain affinity for the receptor; among them, two tertiary bases (37, 38), show affinity in the nanomolar range for the nicotinic receptor. The pharmacological profile of these isomeric compounds is quite interesting as they present differences in their peripheral and central effects, suggesting that they interact with different subtypes of the nicotinic receptor. Copyright (C) 1999 Elsevier Science Ltd.

Mercaptoacylpiperazine carboxylic acid compounds

The mercaptoacylpiperazine carboxylic acid compounds which have the formula STR1 wherein R, R3 and R4 each is hydrogen or lower alkyl; R1 is lower alkyl; R2 is hydrogen, lower alkanoyl, benzoyl or STR2 m is 0, 1 or 2; n is 1, 2 or 3, the sum of m+n being equal to 1, 2 or 3 and salts thereof, are useful as hypotensive agents.